This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome
by Zacks Equity Research
Teva's ecopipam secures FDA priority review for pediatric Tourette syndrome, potentially bringing the first new therapy in over a decade.
TEVANegative Net Change ACIUNegative Net Change AMRXNegative Net Change PGENNegative Net Change
biotechnology
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.
DNLINegative Net Change
biotechnology biotechs medical pharmaceuticals
Reasons Why Investors Should Consider Betting on PGEN Stock
by Zacks Equity Research
Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential.
PGENNegative Net Change MRKNegative Net Change ACIUNegative Net Change AMRXNegative Net Change
biotechnology
Regeneron Secures FDA Approval for Rare Genetic Disorder Drug
by Zacks Equity Research
REGN's Pasatru wins FDA approval for FOP, cutting new HO lesions by 90% or more and reducing clinician-assessed flare-ups.
REGNNegative Net Change SNYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?
by Ahan Chakraborty
NVO's U.S. launch of Awiqli introduces the first once-weekly basal insulin, potentially giving the company a new growth opportunity beyond its pressured GLP-1 franchise.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos
by Zacks Equity Research
Ultragenyx stock rises as Genglycos wins FDA's accelerated approval as the first treatment targeting the underlying cause of GSDIa, boosting its rare-disease portfolio.
RARENegative Net Change RGENNegative Net Change ACIUNegative Net Change AMRXNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Bet on These Biotech ETFs as Innovation Drives Market-Beating Growth
by Aparajita Dutta
Biotech ETFs are riding a powerful rally fueled by innovation, obesity drugs and M&A, with three funds offering diversified exposure to growth.
AMGNNegative Net Change BBHNegative Net Change FBTNegative Net Change BBPNegative Net Change CRNXNegative Net Change
biotechnology etfs
Paylocity (PCTY) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
PCTYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Oatly Group AB Sponsored ADR (OTLY)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
OTLYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Moderna or Merck: Which Soaring Cancer Vaccine Stock Is the Better Buy?
by Shaun Pruitt
Shares of Moderna (MRNA) and Merck (MRK) are soaring Wednesday after the companies reported a potentially historic breakthrough for their personalized mRNA cancer vaccine.
MRKNegative Net Change MRNANegative Net Change
biotechnology cancer cell-therapy dividends genetics hospitals immuno-therapy investing large-cap medical pharmaceuticals